|
⚲
|
| Keyboard |
| Kathleen Clarence-Smith | |
|---|---|
| Firm | |
| Address | c/o Chase Therapeutics Corporation 1825 K Street NW, Suite 510 Washington, DC 20006 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Chase Therapeutics Corp | 021-320230 | Director | 4.0 M of 4.0 M |
||
| GT Biopharma Inc | 021-319563 | Director | 5.1 M of 5.1 M |
||
| GT Biopharma Inc | 021-304968 | Director | 7.1 M of 7.1 M |
||
| Chase Therapeutics Corp | 021-299627 | Director | 1.3 M of 1.3 M |
||
| GT Biopharma Inc | 021-294767 | Executive Officer | 4.5 M of 4.5 M |
||
| Chase Pharmaceuticals Corp | 021-260084 | Executive Officer | 12.0 M of 12.0 M |
||
| Chase Pharmaceuticals Corp | 021-257591 | Executive Officer | of 0.1 M |
||
| Chase Pharmaceuticals Corp | 021-257589 | Executive Officer | of 0.6 M |
||
| Chase Pharmaceuticals Corp | 021-246193 | Executive Officer | 3.5 M of 3.5 M |
||
| Chase Pharmaceuticals Corp | 021-153008 | Executive Officer | 1.2 M of 1.2 M |
||